Get started
Author

Alessandro Paoli

Observed name: A. Paoli
ORCID: 0000-0002-1128-6839
Observed ORCID: 0000-0002-1128-6839
OpenAlex ID: A5101861644
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al. · Clinical Cancer Research · 133
PDF
Notch signaling deregulation in multiple myeloma: A rational molecular target
2015 · Michela Colombo, Serena Galletti, et al. · Oncotarget · 65
PDF
Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening
2017 · Natalia Platonova, Chiara Parravicini, et al. · PLoS ONE · 21
PDF
Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models
2019 · A. Fiascarelli, G. Merlino, et al. · Annals of Oncology · 9
Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
2017 · Paolo Bossi, Marco Siano, et al. · Disease Markers · 6
PDF
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial
2025 · Giovanni Martinelli, Scott R. Solomon, et al. · Blood Neoplasia · 3
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
2021 · Alessandro Paoli, Daniela Bellarosa, et al. · Blood · 3
Elacestrant in Combination with Everolimus for Estrogen Receptor–Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE
2026 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research · 2
Data from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al. · 1
Multiple myeloma-associated drug resistance : targeting the Notch pathway
2015 · S. Garavelli, Elisa Lazzari, et al. · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · 1
PDF
Abstract CT262: Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study
2026 · Hope S. Rugo, Sara M. Tolaney, et al. · Cancer Research
Figure 2 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Figure 3 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Table 2 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Figure 1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Table 1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Supplementary Data1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Table 3 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al.
Abstract PS18-26: Men1611 promotes immune activating myeloid cell polarization
2021 · Stefania Capano, Alessandro Paoli, et al. · Cancer Research
Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study
2017 · D. Raggi, A. Paoli, et al. · Annals of Oncology
Molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib (S-GC) in muscle-invasive urothelial bladder carcinoma (MIBC): Insights for trials of new agents combined with chemotherapy in the field.
2017 · Andrea Necchi, Daniele Raggi, et al. · Journal of Clinical Oncology
Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.
2017 · Maria Di Bartolomeo, Devecchi Andrea, et al. · Journal of Clinical Oncology
A novel Notch-targeted therapeutic approach in multiple myeloma based on small molecules disrupting Notch-Jagged interaction
2015 · Natalia Platonova, Alessandro Paoli, et al.
Targeting the Notch pathway in multiple myeloma through small molecules uncoupling Notch-Jag interaction
2015 · Natalia Platonova, Alessandro Paoli, et al.
Notch pathway and Inteleukin-6 cooperate to support multiple myeloma cell proliferation
2015 · S. Galletti, M. Colombo, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 28
Citation count: 244
H-index: 5
I10-index: 3
Year
Topic
Type